UPSHER-SMITH LABORATORIES

๐Ÿ‡บ๐Ÿ‡ธUnited States
Ownership
-
Established
1919-01-01
Employees
-
Market Cap
-
Website
http://www.upsher-smith.com/

Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old

Phase 4
Recruiting
Conditions
Interventions
First Posted Date
2021-02-10
Last Posted Date
2024-10-18
Lead Sponsor
Upsher-Smith Laboratories
Target Recruit Count
132
Registration Number
NCT04748601
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Upsher-Smith Clinical Trial Site #5, Birmingham, Alabama, United States

๐Ÿ‡บ๐Ÿ‡ธ

Upsher-Smith Clinical Trial Site #15, La Jolla, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Upsher-Smith Clinical Trials Site #3, Aurora, Colorado, United States

and more 12 locations

Vogelxo(R) ABPM Study in Hypogandal Men

Phase 4
Completed
Conditions
Interventions
First Posted Date
2020-09-22
Last Posted Date
2024-10-18
Lead Sponsor
Upsher-Smith Laboratories
Target Recruit Count
122
Registration Number
NCT04558567
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Upsher-Smith Clinical Trial Site #1, Miami, Florida, United States

๐Ÿ‡บ๐Ÿ‡ธ

Upsher-Smith Clinical Trials Site #8, San Antonio, Texas, United States

๐Ÿ‡บ๐Ÿ‡ธ

Upsher-Smith Clinical Trial Site #2, Anaheim, California, United States

and more 4 locations

An Efficacy and Safety Study of DFN-02 (Sumatriptan Nasal Spray 10 mg)

First Posted Date
2016-08-05
Last Posted Date
2021-03-30
Lead Sponsor
Upsher-Smith Laboratories
Target Recruit Count
107
Registration Number
NCT02856802
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Site 33, Mount Pleasant, South Carolina, United States

๐Ÿ‡บ๐Ÿ‡ธ

Site 28, West Jordan, Utah, United States

๐Ÿ‡บ๐Ÿ‡ธ

Site 29, Rochester, New York, United States

and more 6 locations

Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures

Phase 3
Completed
Conditions
Interventions
First Posted Date
2010-08-30
Last Posted Date
2015-02-23
Lead Sponsor
Upsher-Smith Laboratories
Target Recruit Count
210
Registration Number
NCT01191086

Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures

Phase 3
Completed
Conditions
Interventions
First Posted Date
2010-06-11
Last Posted Date
2014-05-22
Lead Sponsor
Upsher-Smith Laboratories
Target Recruit Count
249
Registration Number
NCT01142193

Study to Evaluate Divigel for the Treatment of Postmenoupausal Symptoms

Phase 3
Completed
Conditions
First Posted Date
2008-08-01
Last Posted Date
2008-09-26
Lead Sponsor
Upsher-Smith Laboratories
Target Recruit Count
495
Registration Number
NCT00727129
ยฉ Copyright 2024. All Rights Reserved by MedPath